HDAC9 and neoplasm: YW3-56 has been shown to be a potent inhibitor of tumor growth and metastasis in a variety of preclinical tumor models and has been shown to significantly improve the therapeutic effect when combined with radiotherapy, photothermal therapy, or chemotherapy (e.g., the HDAC inhibitor SAHA) [111,241,250].